Safety and Efficacy of Maytenus Senegalensis for the Treatment of Uncomplicated Malaria
Status:
Enrolling by invitation
Trial end date:
2022-09-25
Target enrollment:
Participant gender:
Summary
Antimalarial Herbal medicine known as Maytenus senegalensis will be evaluated for its safety,
tolerability and efficacy among Tanzanian male adults aged 18 to 45 years. The first primary
objective is to assess the safety and tolerability of malaria herbal remedy of Maytenus
senegalensis among healthy male adults aged 18 to 45 years in Tanzania. And the second
objective is to evaluate the safety, tolerability as well as efficacy of malaria herbal
remedy Maytenus senegalensis (MALHERBAL) for the treatment of Tanzanian adults aged 18 to 45
years with uncomplicated malaria compared to Artemether-lumefantrine.
Phase:
Phase 2
Details
Lead Sponsor:
Ifakara Health Institute
Collaborators:
Muhimbili University of Health and Allied Sciences National Institute for Medical Research, Tanzania Swiss Tropical & Public Health Institute
Treatments:
Artemether Artemether, Lumefantrine Drug Combination Lumefantrine